New Clinical Data Demonstrate that VIVUS' QSYMIA® in Combination with Digitally Enhanced Lifestyle Interventions (DELI) Leads to Significantly Greater Reductions in Weight and Cardiovascular Risk Compared with DELI Alone in Adults with Obesity

Core Insights - VIVUS LLC announced positive results from a randomized trial evaluating QSYMIA in combination with digital lifestyle intervention (DELI) for weight loss and cardiovascular disease risk in adults with obesity [1][2][3] Study Results - The trial involved 80 participants, with 42 receiving QSYMIA and 38 receiving a placebo, focusing on weight loss and atherosclerotic cardiovascular disease (ASCVD) risk [2][5] - At 3 months, participants in the QSYMIA plus DELI group lost an average of 10.82 kg compared to 4.04 kg in the placebo group (P=0.002) [5] - At 12 months, the QSYMIA plus DELI group lost an average of 15.32 kg compared to 5.85 kg in the placebo group (P<0.001) [5] - The QSYMIA group showed a 3.35% reduction in lifetime ASCVD risk compared to the placebo group (P=0.004) [5] - Significant reductions in waist circumference (-12.6 cm vs -2.07 cm, P<0.001), body mass index (-5.07 kg/m² vs -1.88 kg/m²), and diastolic blood pressure (-4.79 mm Hg vs -1.16 mm Hg, P=0.048) were also observed [5] Product Information - QSYMIA is a combination of phentermine and topiramate, indicated for weight loss in adults and certain pediatric patients aged 12 years and older, in conjunction with a reduced-calorie diet and increased physical activity [3][6] - It is noted as the leading non-injectable branded weight loss medication in the U.S. [3] Company Overview - VIVUS is dedicated to developing and commercializing innovative therapies for patients with serious unmet medical needs [4]